Cite

    Abraham, I. et al. (n.d.). Trilaciclib and the economic value of multilineage myeloprotection from chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer treated with first-line chemotherapy. Journal of medical economics. pp. 71-83. [Online].